Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Kiora Pharmaceuticals, formerly EyeGate Pharmaceuticals, has rebranded to reflect its focus on developing innovative ophthalmic therapies, including a groundbreaking treatment for Retinitis Pigmentosa. The company’s pipeline includes three key assets: KIO-101, KIO-301, and KIO-201, each targeting various eye diseases. Upcoming milestones include Phase 1b trial initiation for KIO-301 in late-stage Retinitis Pigmentosa and a pre-IND meeting with the FDA regarding KIO-201. Kiora’s strategy aims to drive value through expanded clinical development efforts.